Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

Constance A. Benson, Steven G. Deeks, Scott C. Brun, Roy M. Gulick, Joseph J. Eron, Harold A. Kessler, Robert L. Murphy, Charles Hicks, Martin King, David Wheeler, Judith Feinberg, Richard Stryker, Paul E. Sax, Sharon Riddler, Melanie Thompson, Kathryn Real, Ann Hsu, Dale Kempf, Anthony J. Japour, Eugene Sun

Research output: Contribution to journalArticlepeer-review

142 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients'. Together they form a unique fingerprint.

Medicine & Life Sciences